HPV-based Screening Among Women 23-29 Years of Age
Launched by KAROLINSKA INSTITUTET · Jan 27, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the best way to screen for the Human Papilloma Virus (HPV) in women aged 23 to 29. HPV is a virus that can lead to cervical cancer, and the study aims to find out if using a test that directly checks for HPV can offer better protection against cancer compared to the standard method, which looks for changes in the cells of the cervix.
To be eligible for this trial, women must be between 23 and 29 years old and are invited to participate in the screening. Unfortunately, if someone does not attend the screening or does not agree to take part, they cannot join the study. If you choose to participate, you will help researchers understand which screening method is more effective in protecting against cervical cancer, which is important for women's health. The trial is currently recruiting participants, so if you fit the age criteria, you might consider getting involved!
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women ages 23-29 invited to screening.
- Exclusion Criteria:
- • Women who do not show up for screening or do not consent.
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, Skåne, Sweden
Stockholm, , Sweden
Lund, , Sweden
Patients applied
Trial Officials
Joakim Dillner, MD, PhD
Principal Investigator
Karolinska University Hospital/Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials